Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: August 30, 2022 Report Code: GDGMDHC22302IDB-ST

Select Item

Asthma Pipeline Drugs Market Overview

Asthma, a chronic disease involving the airways in the lungs, may occur with symptoms that include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing.

The Asthma pipeline drugs market research report outlays comprehensive information on the Asthma targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in Asthma targeted therapeutics development with respective active and dormant or discontinued projects.

Asthma Pipeline Drugs Market Segmentation by Targets

Some of the primary targets in the Asthma pipeline drugs market are Beta 2 Adrenergic Receptor, Glucocorticoid Receptor, Immunoglobulin E ), Interleukin 4 Receptor Subunit Alpha, Thymic Stromal Lymphopoietin, Muscarinic Acetylcholine Receptor M3, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, and Prostaglandin D2 Receptor 2. Beta 2 Adrenergic Receptor accounted for the largest target in the Asthma pipeline drugs market.

Asthma Pipeline Drugs Market Analysis, by Targets

Asthma Pipeline Drugs Market Analysis, by Targets

To know more about the targets in the Asthma pipeline drugs market, download a free report sample

Asthma Pipeline Drugs Market Segmentation by Mechanisms of Action

The primary mechanisms of action in the Asthma pipeline drugs market are Glucocorticoid Receptor Agonist, Beta 2 Adrenergic Receptor Agonist, Immunoglobulin E Inhibitor, Thymic Stromal Lymphopoietin Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Muscarinic Acetylcholine Receptor M3 Antagonist, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, and Prostaglandin D2 Receptor 2 Antagonist. Glucocorticoid Receptor Agonist has the maximum number of products in the Asthma pipeline drugs market.

Asthma Pipeline Drugs Market Analysis, by Mechanisms of Action

Asthma Pipeline Drugs Market Analysis, by Mechanisms of Action

To know more about the MoA in the Asthma pipeline drugs market, download a free report sample

Asthma Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Asthma pipeline drugs market are inhalational, subcutaneous, oral, intravenous, nasal, parenteral, topical, intraarticular, transdermal, and intramuscular. Inhalational has the majority number of products in the Asthma pipeline drugs market.

Asthma Pipeline Drugs Market Analysis, by Routes of Administration

Asthma Pipeline Drugs Market Analysis, by Routes of Administration

To know more about the RoA in the Asthma pipeline drugs market, download a free report sample

Asthma Pipeline Drugs Market Segmentation by Molecule Type

The key molecule types in the Asthma pipeline drugs market are Small Molecule, Monoclonal Antibody, Biologic, Cell Therapy, Recombinant Protein, Antisense Oligonucleotide, Synthetic Peptide, and Allergenics (Allergen) among others.

Asthma Pipeline Drugs Market Analysis, by Molecule Type

Asthma Pipeline Drugs Market Analysis, by Molecule Type

To know more about the molecule type in the Asthma pipeline drugs market, download a free report sample

Competitive Landscape

Some of the leading companies in the Asthma pipeline drugs market are AstraZeneca Plc, GSK plc, MD Healthcare Inc, Novartis AG, Korea United Pharm Inc, Oneness Biotech Co Ltd, GeneScience Pharmaceuticals Co Ltd, JiangSu Qyuns Therapeutics Co Ltd, Mabwell Shanghai Bioscience Co Ltd, and Respiratorius AB among others. AstraZeneca Plc accounted for the largest Asthma pipeline drugs market share in 2021.

Asthma Pipeline Drugs Market Analysis, by Leading Companies

Asthma Pipeline Drugs Market Analysis, by Leading Companies

To know more about the leading companies in the Asthma pipeline drugs market, download a free report sample

Asthma Pipeline Drugs Market Report Overview

Key Targets Beta 2 Adrenergic Receptor, Glucocorticoid Receptor, Immunoglobulin E ), Interleukin 4 Receptor Subunit Alpha, Thymic Stromal Lymphopoietin, Muscarinic Acetylcholine Receptor M3, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, and Prostaglandin D2 Receptor 2
Key Mechanisms of Action Glucocorticoid Receptor Agonist, Beta 2 Adrenergic Receptor Agonist, Immunoglobulin E Inhibitor, Thymic Stromal Lymphopoietin Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Muscarinic Acetylcholine Receptor M3 Antagonist, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, and Prostaglandin D2 Receptor 2 Antagonist
Key Routes of Administration Inhalational, Subcutaneous, Oral, Intravenous, Nasal, Parenteral, Topical, Intraarticular, Transdermal, and Intramuscular
Key Molecule Types Small Molecule, Monoclonal Antibody, Biologic, Cell Therapy, Recombinant Protein, Antisense Oligonucleotide, Synthetic Peptide, and Allergenics (Allergen)
Key Companies AstraZeneca Plc, GSK plc, MD Healthcare Inc, Novartis AG, Korea United Pharm Inc, Oneness Biotech Co Ltd, GeneScience Pharmaceuticals Co Ltd, JiangSu Qyuns Therapeutics Co Ltd, Mabwell Shanghai Bioscience Co Ltd, and Respiratorius AB

Scope

  • The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

2A Pharma AB
3SBio Inc
4D Pharma Plc
AazeinTx Inc
AB Science SA
Actinobac Biomed Inc
Adare Pharma Solutions
Adial Pharmaceuticals Inc
Advagene Biopharma Co Ltd
Aeon Respire Inc
Airbase Breathing Co LLC
Akari Therapeutics Plc
Akeso Inc
Aldeyra Therapeutics Inc
Algomedix Inc
ALK-Abello AS
Allakos Inc
AllerGen NCE Inc
Allergy Therapeutics Plc
Alveolus Bio Inc
Alvotech SA
Amgen Inc
Amtixbio Co Ltd
Amytrx Therapeutics Inc
AnGes Inc
Antisense Therapeutics Ltd
Antlia Bioscience Inc
Apollo Therapeutics LLC
Aquilon Pharmaceuticals SA
Areteia Therapeutics Inc
Argenx SE
Arrowhead Pharmaceuticals Inc
ARS Pharmaceuticals Inc
Artax Biopharma Inc
Artizan Biosciences Inc
ASIT Biotech SA
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Athos Therapeutics Inc
AtoGen Co Ltd
Atrapos Therapeutics LLC
AusBio Ltd
Avalo Therapeutics Inc
Bai Shuo Beijing Pharmaceutical Technology Co Ltd
Bilix Co Ltd
BioArdis LLC
Biocon Ltd
Biohaven Pharmaceutical Holding Company Ltd
BioMe Inc
BiosanaPharma BV
Biosion Inc
Biotoxtech Co Ltd
Bioviz Technologies Pvt Ltd
Boehringer Ingelheim International GmbH
CALYXHA Biotechnologies GmbH
Cantex Pharmaceuticals Inc
Celestial Therapeutics Inc
Celltrion Inc
Celon Pharma SA
Centrymed Pharmaceutical Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chiesi Farmaceutici SpA
Chronic Airway Therapeutics Ltd
Clevexel Pharma SA
Crossject SA
Crystec Ltd
CSL Ltd
CSPC Pharmaceutical Group Ltd
Cumberland Pharmaceuticals Inc
Curateq Biologics Pvt Ltd
Curovir AB
Cynata Therapeutics Ltd
Cytokinetics Inc
Daewoong Pharmaceutical Co Ltd
Defensin Therapeutics ApS
Dnarx LLC
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
EffectorBio Inc
EmphyCorp Inc
Enzychem Lifesciences Corp
Epsilon Molecular Engineering Inc
ethris GmbH
EURRUS Biotech GmbH
F. Hoffmann-La Roche Ltd
Fibrotherapeutics Inc
Foresee Pharmaceuticals Co Ltd
GeneScience Pharmaceuticals Co Ltd
Genrix (Shanghai) Biopharmaceutical Co Ltd
GI Innovation Co Ltd
Glenmark Pharmaceuticals Ltd
GliaCure Inc
GlycoMira Therapeutics Inc
Gossamer Bio Inc
GSK plc
Gurus BioPharm Inc
Harbour BioMed (Guangzhou) Co Ltd
HEC Pharma Co Ltd
Hoth Therapeutics Inc
Hovione FarmaCiencia SA
Hunan Jingfeng Pharmaceutical Co Ltd
iCeutica Inc
Icure Pharmaceutical Inc
IGE Therapeutics Inc
ILiAD Biotechnologies LLC
ImmuNext Inc
Immupharma Plc
Inatherys
Incannex Healthcare Ltd
Inmagene Biopharmaceuticals Ltd
Inmunotek SL
InnoPharmaScreen Inc
Innovimmune Biotherapeutics Inc
InStatin Inc
Invion Ltd
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
Irex Pharma LLC
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Jiye Biopharmaceutical Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Joincare Pharmaceutical Group Industry Co Ltd
JW Pharmaceutical Corp
Kashiv BioSciences LLC
KBP Biosciences Co Ltd
KeyMed Biosciences Inc
Kinaset Therapeutics Inc
Kissei Pharmaceutical Co Ltd
Kither Biotech Srl
KLUS Pharma Inc
KoBioLabs Inc
Korea United Pharm Inc
Kymab Ltd
Kyowa Kirin Co Ltd
Landos Biopharma Inc
Lanier Biotherapeutics Inc
Laurel Therapeutics
Lead Discovery Center GmbH
Lignamed LLC
Liminal BioSciences Inc
Longevity Biotech Inc
Luye Pharma Group Ltd
Mabpharm Ltd
Mabtech Ltd
Mabwell Shanghai Bioscience Co Ltd
Mariposa Health Ltd
MD Healthcare Inc
Mercia Pharma Inc
Merck & Co Inc
MitoImmune Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Molecure SA
Mycenax Biotech Inc
NAL Pharmaceuticals Ltd
NeoPharm Co Ltd
Neovacs SA
NeuImmune Inc
Nexeos Bio
NightHawk Biosciences Inc
NovaCell Technology Inc
NovaRock Biotherapeutics Inc
Novartis AG
Nuvara Therapeutics LLC
Oak Hill Bio Inc
OM Pharma Ltd
Omeros Corp
Oneness Biotech Co Ltd
Opsidio LLC
Orchid Pharma Ltd
Orphomed Inc
Ossium Health Inc
Palo BioFarma SL
Pantherics Inc
Paradigm Biopharmaceuticals Ltd
Parmedics Inc
Pfizer Inc
PharmAbcine Inc
PharmaKing Co Ltd
Pharmaxis Ltd
Principia Biopharma Inc
Progenra Inc
Prommune Inc
Prous Institute for Biomedical Research SA
PSK Pharma Pvt Ltd
Pulmatrix Inc
Pulmokine Inc
Qu Biologics Inc
Quench Medical Inc
Qurient Co Ltd
RAFT Pharmaceuticals
RAGE Biotech Pty Ltd
RAPT Therapeutics Inc
ReAlta Life Sciences Inc
Rebus Holdings Inc
Regeneron Pharmaceuticals Inc
Respiratorius AB
Revalesio Corp
Revolo Biotherapeutics Ltd
Ribomic Inc
Ribon Therapeutics Inc
RS BioTherapeutics Inc
S-TARget therapeutics GmbH
Sama Pharm Co Ltd
Sanofi
Santhera Pharmaceuticals Holding AG
Seelos Therapeutics, Inc.
Shandong Boan Biotechnology Co Ltd
Shanghai KE Pharmaceutical Co Ltd
Shanghai Kexin Biotech Co Ltd
Shanghai Mabgeek Biotechnology Co., Ltd
Shanghai Meiji Biotechnology Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Shenzhen Forward Pharmaceutical Co Ltd
Shouyao Holding Co Ltd
Sichuan Yuanda Shuyang Pharmaceutical Co Ltd
Siolta Therapeutics Inc
SolAeroMed Inc
SpliSense Ltd
sterna biologicals Gmbh & Co KG
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Kanova Biomedical Technology Co Ltd
Synermore Biologics Co Ltd
Taiho Pharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
TAK-Circulator Corp
Tarus Therapeutics Inc
TCF GmbH
Tetherex Pharmaceuticals Corp
Tetragenetics Inc
TFF Pharmaceuticals Inc
The Geneva Biotech Center SA
The United Laboratories International Holdings Ltd
Tianchen Biopharmaceutical (Suzhou) Co Ltd
Torrent Pharmaceuticals Ltd
Translational Biosciences
Transpire Bio Inc
Trio Medicines Ltd
United Biomedical Inc
Upstream Bio Inc
Vactech Oy
ValenzaBio Inc
Vanworld Pharmaceutical (Rugao) Company Ltd
Vascular BioSciences
Vasomune Inc
Vectura Group Plc
Verona Pharma Plc
VGSK Technologies Inc
Vicenna Pharmaceuticals Inc
Virtici LLC
Wuhan Healthgen Biotechnology Corp
YSOPIA Bioscience SA
Yuhan Corp
Zhejiang Hisun Pharmaceutical Co Ltd
Zhengda Tianqing Pharmaceutical Group Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Asthma – Overview

Asthma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Asthma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Asthma – Companies Involved in Therapeutics Development

Asthma – Drug Profiles

Asthma – Dormant Projects

Asthma – Discontinued Products

Asthma – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Asthma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Asthma – Dormant Projects, 2022

Asthma – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Asthma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the targets in the Asthma pipeline drugs market?

    Some of the targets in the Asthma pipeline drugs market are Beta 2 Adrenergic Receptor, Glucocorticoid Receptor, Immunoglobulin E ), Interleukin 4 Receptor Subunit Alpha, Thymic Stromal Lymphopoietin, Muscarinic Acetylcholine Receptor M3, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, and Prostaglandin D2 Receptor 2 among others.

  • What are the mechanisms of action in the Asthma pipeline drugs market?

    The primary mechanism of action in the Asthma pipeline drugs market are Glucocorticoid Receptor Agonist, Beta 2 Adrenergic Receptor Agonist, Immunoglobulin E Inhibitor, Thymic Stromal Lymphopoietin Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Muscarinic Acetylcholine Receptor M3 Antagonist, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, and Prostaglandin D2 Receptor 2 Antagonist among others.

  • What are the routes of administration in the Asthma pipeline drugs market?

    The routes of administration in the Asthma pipeline drugs market are Inhalational, Subcutaneous, Oral, Intravenous, Nasal, Parenteral, Topical, Intraarticular, Transdermal, and Intramuscular among others.

  • What are the molecule types in the Asthma pipeline drugs market?

    The molecule types in the Asthma pipeline drugs market are Small Molecule, Monoclonal Antibody, Biologic, Cell Therapy, Recombinant Protein, Antisense Oligonucleotide, Synthetic Peptide, and Allergenics (Allergen) among others.

  • Which are the leading companies in the Asthma pipeline drugs market?

    Some of the leading companies in the Asthma pipeline drugs market are AstraZeneca Plc, GSK plc, MD Healthcare Inc, Novartis AG, Korea United Pharm Inc, Oneness Biotech Co Ltd, GeneScience Pharmaceuticals Co Ltd, JiangSu Qyuns Therapeutics Co Ltd, Mabwell Shanghai Bioscience Co Ltd, and Respiratorius AB among others.

Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Respiratory reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more